BofA sees long-term value in K-C's Kenvue deal; KVUE holders eye regulatory path

What happened

Bank of America reiterated its 'Buy' rating on Kimberly-Clark with a $120 price target, citing the opportunistic acquisition of Kenvue at roughly 14x EBITDA as a long-term value creator despite near-term integration hurdles. For KVUE shareholders, the stock continues to behave as a merger-arb instrument, with U.S. antitrust clearance and shareholder votes secured, leaving foreign regulatory approvals and the FDA's acetaminophen labeling review as the remaining binary catalysts. The base case assumes 2H26 closing without material divestitures, but the company's own filings warn that regulators may demand remedies that could alter deal economics. Meanwhile, the FDA's label change process for Tylenol poses a dual threat: it could depress sales and amplify litigation risk, potentially delaying or complicating the close. Spread compression from current levels thus hinges on a steady cadence of foreign approvals and no adverse FDA action over the next 6–12 months.

Implication

Investors should track non-U.S. regulatory approvals for signs of remedy demands, as any requirement for divestitures would undermine deal value and widen spreads. The FDA's acetaminophen label decision is the other key variable; a final order with near-term compliance could pressure sales and increase the probability of a deal break or renegotiation. Position sizing must account for a potential 20–25% downside if the transaction fails, given KVUE's weak standalone volume trends and lack of near-term catalysts. We would consider adding only if foreign clearance cadence becomes visible and FDA risks recede.

Thesis delta

The investment thesis for KVUE shifts from a near-complete merger arb (U.S. clearance and shareholder votes done) to a phase dominated by foreign regulatory and FDA label risks. Previously, the main gating item was domestic antitrust and shareholder approval, both now resolved. The focus now is on whether foreign regulators demand remedies and whether the FDA accelerates its acetaminophen label change—either could disrupt the 2H26 closing timeline and stand-alone valuation floor.